Virginia K Crosson Cancer Center
Welcome,         Profile    Billing    Logout  
 11 Trials 
31 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Patel, Manali
NCT03154190: Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer

Active, not recruiting
N/A
128
US
Best Practice, standard of care, standard therapy, Laboratory Biomarker Analysis, Supportive Care, Supportive Therapy, Symptom Management, Therapy, Supportive, Survey Administration
Stanford University
Acute Myeloid Leukemia, Brain Glioblastoma, Estrogen Receptor Negative, Extensive Stage Small Cell Lung Carcinoma, Head and Neck Carcinoma, HER2/Neu Negative, Hormone-Resistant Prostate Cancer, Limited Stage Small Cell Lung Carcinoma, Myelodysplastic Syndrome, Progesterone Receptor Negative, Progressive Disease, Recurrent Carcinoma, Stage II Pancreatic Cancer, Stage II Rectal Cancer, Stage IIA Pancreatic Cancer, Stage IIA Rectal Cancer, Stage IIB Pancreatic Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage III Colon Cancer, Stage III Esophageal Cancer, Stage III Gastric Cancer, Stage III Non-Small Cell Lung Cancer, Stage III Ovarian Cancer, Stage III Pancreatic Cancer, Stage III Rectal Cancer, Stage III Skin Melanoma, Stage IIIA Colon Cancer, Stage IIIA Esophageal Cancer, Stage IIIA Gastric Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Rectal Cancer, Stage IIIA Skin Melanoma, Stage IIIB Colon Cancer, Stage IIIB Esophageal Cancer, Stage IIIB Gastric Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Rectal Cancer, Stage IIIB Skin Melanoma, Stage IIIC Colon Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Gastric Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Rectal Cancer, Stage IIIC Skin Melanoma, Stage IV Bladder Cancer, Stage IV Bone Sarcoma, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Ovarian Cancer, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Stage IV Renal Cell Cancer, Stage IV Skin Melanoma, Stage IV Soft Tissue Sarcoma, Stage IVA Bone Sarcoma, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Bone Sarcoma, Stage IVB Colon Cancer, Stage IVB Rectal Cancer, Triple-Negative Breast Carcinoma
11/21
08/22
LEAPS, NCT03699748: Lay Health Worker Engage, Educate, and Encourage Patients to Share

Completed
N/A
160
US
Lay Health Worker Intervention, Usual Care
Stanford University, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD)
End of Life, Cancer
12/21
12/22
NCT03216109: Improving Supportive Care For Patients With Thoracic Malignancies

Completed
N/A
60
US
Weekly telephone symptom assessment
Palo Alto Veterans Institute for Research, Carevive Systems, Inc.
Lung Cancer, Quality of Life, Supportive Care
06/23
12/23
NCT05916378: Achieving Equity in Genomic Testing for Breast Cancer Through Partner-Led Strategies and Policies

Active, not recruiting
N/A
150
US
Stanford University, The Latino Cancer Institute
Breast Cancer
10/24
03/25
NCT05947357: Food for Health Equity: Evaluation of a Nutrition Assistance Program

Recruiting
N/A
30
US
Nutrition Assistance Program
Stanford University
Cancer
12/25
12/25
NCT05795959: Ensuring Precision-Medicine Delivery for Veterans With Lung Cancer

Completed
N/A
46
US
Receive education on precision medicine
Stanford University
Lung Cancer
05/24
05/24
NCT04330521: Impact of the Coronavirus (COVID-19) on Patients With Cancer

Recruiting
N/A
50
US
Stanford University
Cancer, COVID-19
05/26
05/26
NCT04463992: Lay Health Worker Expanded Intervention in Community Oncology Practices

Completed
N/A
416
US
Program participants, Usual Care
Stanford University
End of Life, Cancer
10/24
10/24
NCT05297734: Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer

Recruiting
N/A
2996
US
Receive technology-based supportive cancer care, Technology-based SCC approach, Receive redesigned team-based supportive cancer care, Patients Activated in Cancer care through Teams (PACT), Redesigned SCC team-based approach
Stanford University, Patient-Centered Outcomes Research Institute
End of Life, Cancer
01/28
02/28
Park, David
NCT05354141: Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)

Recruiting
3
970
US
ExoFlo, Intravenous normal saline
Direct Biologics, LLC
Acute Respiratory Distress Syndrome, ARDS
03/25
08/25
ASTRIDE, NCT05468489: To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

Recruiting
3
200
US
Serplulimab + chemotherapy (carboplatin-etoposide), Atezolizumab + chemotherapy (carboplatin-etoposide)
Shanghai Henlius Biotech
Extensive Stage Small Cell Lung Cancer
04/25
12/25
LUNAR-2, NCT06216301: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

Recruiting
3
734
Europe, Japan, US, RoW
NovoTTF-200T, Pembrolizumab, Platinum based chemotherapy
NovoCure GmbH
Metastatic Non-small Cell Lung Cancer
10/28
10/28
PANOVA-3, NCT03377491: Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel

Completed
3
571
Europe, Canada, US, RoW
NovoTTF-200T, TTFields, Gemcitabine, nab paclitaxel
NovoCure Ltd.
Pancreas Adenocarcinoma
10/24
10/24
Be6A Lung-01, NCT06012435: A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer ().

Recruiting
3
600
Europe, Canada, Japan, US, RoW
sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel
Seagen Inc.
Carcinoma, Non-Small-Cell Lung
07/26
07/28
CompassHER2 RD, NCT04457596: T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the Trial

Calendar Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer
Recruiting
3
1031
Canada, US
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Anatomic Stage IA Breast Cancer AJCC V8, Anatomic Stage II Breast Cancer AJCC V8, Anatomic Stage IIA Breast Cancer AJCC V8, Anatomic Stage IIB Breast Cancer AJCC V8, Anatomic Stage III Breast Cancer AJCC V8, Anatomic Stage IIIA Breast Cancer AJCC V8, Anatomic Stage IIIB Breast Cancer AJCC V8, Anatomic Stage IIIC Breast Cancer AJCC V8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC V8, Prognostic Stage IA Breast Cancer AJCC V8, Prognostic Stage IB Breast Cancer AJCC V8, Prognostic Stage II Breast Cancer AJCC V8, Prognostic Stage IIA Breast Cancer AJCC V8, Prognostic Stage IIB Breast Cancer AJCC V8, Prognostic Stage III Breast Cancer AJCC V8, Prognostic Stage IIIA Breast Cancer AJCC V8, Prognostic Stage IIIB Breast Cancer AJCC V8, Prognostic Stage IIIC Breast Cancer AJCC V8, Synchronous Bilateral Breast Carcinoma
01/28
05/35
NCT04780685: A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19

Recruiting
2
40
US
hMSC, allogeneic mesenchymal bone marrow cells
Stemedica Cell Technologies, Inc., bioRASI, LLC
Covid19
09/22
12/22
NCT05529316: A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

Active, not recruiting
2
220
Europe, US, RoW
Botensilimab, AGEN1181, Balstilimab, AGEN2034
Agenus Inc.
Advanced Melanoma
05/28
05/28
BOLSTER, NCT05712356: A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors

Recruiting
2
80
Europe, US
LSTA1, certepetide, CEND-1, Durvalumab, Imfinzi, Cisplatin, Gemcitabine, FOLFOX regimen, Oxaliplatin, Folinic acid, Fluorouracil, Placebo
Lisata Therapeutics, Inc.
Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Bile Duct Cancer, Gall Bladder Cancer, Gall Bladder Carcinoma
03/26
03/26
NCT06061809: N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma

Recruiting
2
20
US
Bevacizumab, Avastin, PD-L1 t-haNK, N-803, ALT-803, Anktiva
ImmunityBio, Inc.
Glioblastoma
12/29
12/30
1-BETTER, NCT04825288: XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer

Completed
1/2
76
US
XB2001 or Placebo
XBiotech, Inc.
Pancreatic Cancer
10/23
06/24
ELU-FRα-1, NCT05001282: A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

Terminated
1/2
79
US
ELU001, FA-CDC
Elucida Oncology
Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Endometrial Cancer, Ovary Cancer, Ovary Neoplasm, Ovary Disease, Ovary Metastasis, Ovarian Diseases, Ovarian Cancer Stage, Ovarian Epithelial Cancer, Ovarian Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Neoplasm Epithelial, Ovarian Cancer Recurrent, Endometrial Diseases, Endometrial Adenocarcinoma, Endometrial Carcinosarcoma, Endometrial Clear Cell Adenocarcinoma, Endometrioid Adenocarcinoma, Endometrial Neoplasms, Endometrial Cancer Recurrent, Endometrioid Tumor, Fallopian Tube Cancer, Peritoneal Cancer
06/24
06/24
DRAGON, NCT04291079: SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors

Active, not recruiting
1
112
US, RoW
SRK-181, anti-PD-(L)1 antibody therapy
Scholar Rock, Inc.
Cancer
12/24
12/24
RGX-202-001, NCT03597581: A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer

Recruiting
1
108
US
ompenaclid, RGX-202-01, FOLFIRI, Bevacizumab, FOLFOX regimen
Inspirna, Inc.
Gastrointestinal Cancer, Gastrointestinal Neoplasms, Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Gastric Cancer, Gastric Neoplasm, KRAS Mutation-Related Tumors, CRC, Colorectal Cancer Metastatic
12/24
12/24
KN-8701, NCT04913285: A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

Recruiting
1
400
Europe, US, RoW
KIN-2787, exarafenib, KIN-2787 and binimetinib, exarafenib and binimetinib
Pierre Fabre Medicament
Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma
12/24
12/25
NEBULA, NCT05043714: Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours

Checkmark Initiation of trial in combination with NG-641
Sep 2021 - Sep 2021: Initiation of trial in combination with NG-641
Active, not recruiting
1
30
Europe, US
NG-641 in combination with Nivolumab
Akamis Bio, Bristol-Myers Squibb
Metastatic Cancer, Epithelial Tumor
08/24
12/24
HBI-2376-101, NCT05163028: A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations

Recruiting
1
42
US
HBI-2376
HUYABIO International, LLC.
Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor, Cancer, Cancer of Pancreas, Cancer of Colon
12/24
12/24
NCT05159440: First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer

Active, not recruiting
1
70
US, RoW
TORL-2-307-MAB
TORL Biotherapeutics, LLC, Translational Research in Oncology
Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma
12/24
12/25
NCT05156866: First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer

Recruiting
1
70
US, RoW
TORL-2-307-ADC
TORL Biotherapeutics, LLC, Translational Research in Oncology
Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma
01/25
01/26
FORTIFY, NCT05165433: Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours

Active, not recruiting
1
198
Europe, US
NG-350A plus Pembrolizumab, KEYTRUDA®
Akamis Bio, Merck Sharp & Dohme LLC
Epithelial Tumor, Metastatic Cancer
03/25
05/25
TRIDENT, NCT04471844: Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant with RT & TMZ for the Treatment of Newly Diagnosed GBM

Active, not recruiting
N/A
982
Europe, Canada, Japan, US, RoW
Optune®
NovoCure Ltd.
Glioblastoma Multiforme
01/26
01/26
NCT05297734: Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer

Recruiting
N/A
2996
US
Receive technology-based supportive cancer care, Technology-based SCC approach, Receive redesigned team-based supportive cancer care, Patients Activated in Cancer care through Teams (PACT), Redesigned SCC team-based approach
Stanford University, Patient-Centered Outcomes Research Institute
End of Life, Cancer
01/28
02/28

Download Options